Policy & Regulation
Pfizer reports positive early results in PREVNAR 20 and Pfizer/BioNTech COVID-19 vaccine co-administration trial in older adults
13 January 2022 -

US pharmaceutical company Pfizer Inc (NYSE:PFE) announced on Wednesday positive top-line results of a Phase 3 study exploring co-administration of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) with the Pfizer/BioNTech COVID-19 vaccine in older adults.

PREVNAR 20 is Pfizer's next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) already included in PREVNAR 13 (Pneumococcal 13-valent ConjugateVaccine [Diphtheria CRM197 Protein]). The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease (IPD) and have been associated with high case-fatality rates, antibiotic resistance, and/or meningitis. According to Pfizer, PREVNAR 20 contains the broadest conjugate serotype coverage and helps protect against more strains of the bacteria that cause pneumococcal pneumonia than any other conjugate vaccine available.

Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the Pfizer/BioNTech vaccine or with placebo. Also, responses to a booster dose of the Pfizer/BioNTech vaccine were similar when given with PREVNAR 20 or with placebo. The safety profile of co-administering PREVNAR 20 with a booster dose of the Pfizer/BioNTech COVID-19 vaccine generally reflected that observed with the Pfizer/BioNTech booster dose, Pfizer said.

Currently, the PREVNAR 20 and Pfizer/BioNTech COVID-19 vaccine prescribing information does not include co-administration data.

Login
Username:

Password:


Related Headlines